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Open accAbstract Background: To compare colorectal cancer survivors with a normative population
regarding erectile dysfunction, ejaculation problems, dyspareunia, dry vagina, sexual function-
ing (SF) and enjoyment (SE). In addition, the sociodemographic, clinical and psychological
correlates of (dys)function in survivors are examined.
Patients and methods: The European Organisation for Research and Treatment of Cancer
(EORTC) QLQ-CR38 sexuality subscales were completed by survivors (n = 1371; response
rate 82%), of which 1359 received surgical treatment and were included in the analysis. The
normative population consisted of 400 participants (response rate 78%).
Results: Erectile problems were more often present in rectal cancer (54%) than colon cancer
survivors (25%) and the normative population (27%; p < .0001). They also had more ejacula-
tion problems (68%) than colon cancer survivors (47%; p < .001). Dry vagina was common in
colon (28%) and rectal cancer survivors (35%), while the normative population scored lower
(5%; p = .003). In addition, colon (9%) and rectal cancer survivors (30%) experienced more
pain during intercourse than the normative population (0%; p = .001). SE for men was similar04
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3162 B.L. Den Oudsten et al. / European Journal of Cancer 48 (2012) 3161–3170across groups, while women with colorectal cancer reported lower scores than the normative
population. Higher age, being a woman, not having a partner, a low educational level, rectal
cancer, depressive symptoms and fatigue were associated with lower SF. Lower SE was asso-
ciated with higher age and being a woman, depressive symptoms and cardiovascular disease.
Conclusion: SF was deteriorated in both sexes after cancer, which affected women’s SE neg-
atively. Attention towards sexual (dys)function in colorectal cancer survivors is needed.
 2012 Elsevier Ltd.Open access under the Elsevier OA license. 1. Introduction
Colorectal cancer is the third most common cancer in
men (10%), and the second most common cancer in
women.1 Due to medical advances about 62% of the
patients will become long-term survivors,2,3 especially
in younger cohorts.4
Conventionally, outcomes assessment in colorectal
cancer included mortality, morbidity, disease recurrence
and long-term survival. However, patient-reported out-
comes (e.g. quality of life) are now also regarded as
key measurements in assessing outcomes of interven-
tions.5 Sexuality and intimacy are considered to be
important aspects of quality of life.6 The majority of
colorectal cancer survivors often remain sexually
active.7 However, survivors do experience sexual dys-
function, which may be caused by surgical treatment,
radiochemotherapy,7–9 or the presence of a stoma.7 In
addition, sexual functioning and sexual satisfaction are
inﬂuenced by the presence of depressive symptoms,
anxiety and fatigue.10–12
In a recent literature review (n = 82), about half of
the studies had small samples sizes (n < 75) and pre-
sented data for both men and women.7 In addition, only
four studies have used a healthy population as a control
group.13–16 Since, the majority of studies did not include
an age- and sex-matched normative population, it is
often unclear whether sexual dysfunction is purely
related to age or comorbidities. Therefore, the aim of
this large population-based study was to examine (i)
the prevalence of erectile dysfunction, ejaculation prob-
lems, dyspareunia and dry vagina in colon and rectal
cancer survivors and a normative population; (ii) to
compare sexual (dys)function between these three
groups and (iii) to describe the sociodemographic, clini-
cal and psychological correlates of sexual (dys)function
in survivors.2. Methods
2.1. Participants
The Eindhoven Cancer Registry (ECR) records data
of all newly diagnosed individuals with cancer in the
southern part of the Netherlands, an area with 2.3 mil-
lion inhabitants, 10 hospitals with 18 locations and
two large radiotherapy institutes.17 Registered individu-als diagnosed with colorectal cancer between 1998 and
2007 were eligible for participation (n = 5580). From
these survivors, a weighted random selection of 2400
survivors based on tumour, sex and year of diagnosis
was made (Fig. 1). These weights were derived from
the distribution of colon and rectal cancer survivors in
the normative population. Survivors with shorter dura-
tion since diagnosis were oversampled for inclusion in
future follow-up assessments. After excluding survivors
who had cognitive impairment or had died, data collec-
tion started in January 2009. Survivors were informed of
the study via a letter from their (ex)attending surgeon. A
Medical Ethics Committee approved this study. Partici-
pants provided informed consent.
The normative sample was derived from CentERdata
(an online household panel) in which 1731 (81%) mem-
bers of this panel completed questionnaires.18 The
description of the data collection is given elsewhere.18
For this analysis, an age-matched normative population
(n = 400), in which a similar distribution of ages as in
the survivor sample was obtained, was included. The
data will be available for non-commercial scientiﬁc
research, subject to study question, privacy and
conﬁdentiality restrictions and registration (www.
proﬁlesregistry.nl).192.2. Measures
Survivors’ sociodemographic and clinical informa-
tion (i.e. date of diagnosis, Tumour-Node-Metastasis
classiﬁcation,20 clinical stage,20 treatment) was available
from the ECR. Living situation, education, work situa-
tion, length and weight and life style factors were com-
pleted in the questionnaire. An adapted Self-
administered Comorbidity Questionnaire (SCQ) was
completed.21 Disease-speciﬁc issues were assessed with
the European Organisation for Research and Treatment
of Cancer (EORTC) module Quality of Life Question-
naire-Colorectal 38 (QLQ-CR38).22 The QLQ-CR38
comprises 38 questions, of which 19 are completed by
all survivors and the remaining by subsets of survivors
(men or women; survivors with/without a stoma). The
QLQ-CR38 assesses both functioning (weight loss, body
image, sexual functioning (SF), sexual enjoyment (SE),
future perspective) and symptom burden (micturition
problems, defecation problems, gastrointestinal symp-
toms, stoma-related problems, chemotherapy side
5399 survivors ≤85 years at time of study and 
registered with rectal cancer between 1998 and 2007 
and living in the region of the ECR1
2219 survivors randomly selected using weights on 
tumor site, incident year and sex  
1 hospital declined participation: 279 Specialists from 10 hospital locations received an 
invitation letter to participate in this study 
Double selections: 39 
Unverifiable address: 150 
Patient demented/terminally ill: 6 
Tumor not staged: 56 
Initial diagnosis outside ECR: 7 
Status of the remaining 1940 survivors checked 
against ECR1 and hospital records 
A questionnaire was sent to the remaining 1682 
survivors 
311 (18%) patients did not complete the 
questionnaire of whom 70 actively refused or 
were too ill 1371 (82%) survivors returned a completed 
questionnaire  
1359 survivors treated with surgery (with or without 
(neo)adjuvant therapy) were included. 
The participating survivors consisted of 765 men: 468 
colon- and 297 rectal cancer survivors, of which 
respectively 243 and 140 were sexually active   
For women, 594 participated: 434 colon- and 160 rectal 
cancer survivors of which 136 and 59 were sexually 
active.  
For the regression analyses men and women who 
completed the sexuality questions were analyzed as one 
group (n=906). Only sexually active survivors were 
included sexual enjoyment (n=397), male sexual 
functioning (279), and female (156) sexual functioning 
analyses.
Fig. 1. Flow-chart of the data collection process in colorectal cancer survivors. 1ECR: Eindhoven Cancer Registry.
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rating scale ranging from 1 (not at all) to 4 (very much).
Scales were linearly converted to a 0–100 scale. Higher
scores on functional items/scales indicate better func-
tioning, while higher scores on symptom item/scale indi-
cate higher symptom burden. In this study, SF, SE and
male SF or female SF were analysed.
The Fatigue Assessment Scale (FAS)23 is a 10-item
questionnaire assessing perceived fatigue and exhaus-
tion. Five questions of the FAS reﬂect physical fatigue
and ﬁve assess mental fatigue. The response scale is a
5-point rating scale ranging from 1 (never) to 5 (always).
Scores on the FAS range from 10 to 50. The psychomet-
ric properties are good.24–27
Symptoms of anxiety and depression were evaluated
with the 14-item Hospital Anxiety and Depression Scale
(HADS).28 This self-report questionnaire contains two
7-item subscales designed to measure symptoms of anxi-ety and depression. The scale was developed for use in
patients suﬀering from bodily disease and therefore,
symptoms of somatic reference such as pain and fatigue
were excluded. The psychometric properties are
good.29,30
The normative sample completed a sociodemograph-
ic questionnaire, the SCQ and the EORTC QLQ-CR38
sexuality questions, except for the item on ejaculation
diﬃculties since the CentERpanel strongly advised not
to include this speciﬁc item due to practical and ethical
considerations.
2.3. Statistical analyses
Chi-square tests and independent student t-tests were
used to compare both sexes on sociodemographic and
clinical characteristics (for colon-, rectal cancer survivors
and the normative population separately) and sexually
3164 B.L. Den Oudsten et al. / European Journal of Cancer 48 (2012) 3161–3170active survivors with survivors who were not sexually
active. To determine the prevalence of sexual problems,
the scores on the subscales were dichotomised. Partici-
pants who reported no problems or minor problems
(not at all–a little bit) were categorised as not having sex-
ual problems, while patients who reported quite some
problems or severe problems (quite some–verymuch) were
categorised as having sexual problems. ANOVA’s were
conducted for the sexuality subscales, again for men
andwomen separately. Post-hoc tests were corrected with
the Bonferonni method. Finally, multivariate linear
regression models (method: Enter) investigated whether
a priori determined sociodemographic characteristics
(age, sex, having a partner, educational level, Body Mass
Index, being a smoker), clinical and psychological charac-
teristics (site of cancer, type of treatment, years since diag-
nosis, disease progression, having a stoma, having
cardiovascular disease, having diabetes mellitus, fatigue,
anxiety and depression) were associated with SF, SE,
male SF and female SF. Assumptions were checked. SF
was analysed for the entire group, while the other scales
were only examined for the sexually active survivors.
Means and standard deviations are provided as
(M ± SD). Statistical diﬀerences were indicated if
p < .05 (two-sided). A diﬀerence of 0.5 SD was consid-
ered indicative of clinical meaningful diﬀerences between
groups.31 All statistical analyses were performed using
SPSS17.0.
3. Results
In total, 1371 (82%) survivors completed the ques-
tionnaire. Eventually, 1359 survivors treated with sur-
gery (with or without (neo)adjuvant therapy) were
included. Non-respondents were signiﬁcantly older
(72 ± 10) and more often women (55%) than respon-
dents (70 ± 10, 43% female) and those with non-veriﬁed
addresses (69 ± 11, 44% female). These groups did not
diﬀer on clinical aspects.
Male participantsweremore often partnered andmore
highly educated, while they less often had arthrosis and
back pain than women (Table 1). In addition, female
colon cancer survivorsweremore often depressed and less
sexually active than men. Male rectal cancer survivors
were more often smokers than their female counterparts.
Sexually active participants were signiﬁcantly youn-
ger, more often partnered and had a higher educational
level than participants who were not sexually active. In
addition, sexually active men less often had a stoma
and sexually active women less often reported comor-
bidities (Table 2).
The normative sample consisted of 224 men and 156
women (response rate 78%). Men were older (70 ± 10)
than women (67 ± 11, p = .009), were more often part-
nered (80% versus 65%, p = .001), and were more often
sexually active (64% versus 45%, p < .001). Further
information is published elsewhere.32,333.1. Sexual dysfunction
Male colon (58%) and rectal cancer survivors (51%)
were less sexually active than men from the normative
population (64%, p = .018). For women, 54% of colon
cancer survivors were sexually active compared to 23%
for both rectum cancer survivors and the normative
population (p = .345). Male rectal cancer survivors
had more problems with erectile functioning (54%) than
colon cancer survivors (25%) and the normative popula-
tion (27%, p < .0001). Furthermore, male rectal cancer
survivors reported more ejaculation problems (68%)
than colon cancer survivors (47%, p < .001). Lubrication
problems were more common in female colon (28%) and
rectal cancer survivors (35%) than the normative popu-
lation (5%, p = .003). In addition, female colon (9%)
and rectal cancer survivors (30%) experienced more dys-
pareunia than the normative population (0%, p < .001).
Compared with male colon (29 ± 25) and rectal
cancer survivors (26 ± 23), men from the normative
population had higher scores on SF (38 ± 24,
p < .0001; Fig. 2A). However, SE was similar in these
groups. Finally, rectal cancer survivors (52 ± 39)
reported more problems with erectile functioning than
colon cancer survivors (31 ± 35, p < .0001) and the
normative population (29 ± 34, p < .0001).
Female colon (15 ± 19) and rectal cancer survivors
(15 ± 18), reported lower SF than the normative popu-
lation (22 ± 24) (p = .020 and p = .010, respectively;
Fig. 2B), as well as lower SE than the normative popu-
lation (51 ± 29, 49 ± 26 and 66 ± 28, respectively).
Female colon (23 ± 26) and rectal cancer (30 ± 33) sur-
vivors reported signiﬁcantly more problems with female
SF than the normative population (11 ± 17; p = .002).
The diﬀerences in SF and SE in both sexes were clini-
cally meaningful.3.2. Correlates of SF in colorectal cancer survivors
Lower SF was signiﬁcantly associated with higher
age, female sex, not having a partner, low educational
level, rectal cancer, depressive symptoms and fatigue,
explaining 32% of the variance (R2; p < .0001) (Table 3).
Lower SE was associated with higher age, female sex,
depressive symptoms and cardiovascular disease
(R2 = 23%; p < .0001). A lower male SF was associated
with a higher age and having a stoma (R2 = 28%;
p < .0001). Fatigue was associated with a lower females
SF (R2 = 24%; p < .0001).
Secondary analyses stratiﬁed by sex were conducted
in order to determine the sex-speciﬁc correlates of SF
and SE. For men, the results remained comparable,
however, a higher BMI was also related with a lower
SF (R2 = 32%, p < .0001). For women, only a higher
age and having a partner remained signiﬁcantly associ-
ated with SF (R2 = 29%; p < .0001). For men, lower
Table 1
Demographic and clinical characteristics of the participating cancer survivors according to site and sex.
Colon p-Value Rectum p-Value
Men
N = 468
Women
N = 434
Men
N = 297
Women
N = 160
Age at time of survey (mean ± SD) 70.4 ± 9.2 69.9 ±10.1 .486 68.6 ± 9.4 67.6 ± 10.1 .298
Years since initial diagnosis (mean ± SD) 3.9 ± 2.4 3.9 ± 2.5 .701 3.9 ± 2.5 4.2 ± 2.6 .168
BMI (mean ± SD) 27.0 ± 3.9 27.0 ± 5.5 .961 26.4 ± 4.2 26.0 ± 4.7 .491
N (%) N (%) N (%) N (%)
Having a partner
Yes 382 (82) 238 (55) <.0001 248 (84) 107 (67) <.0001
Missing 15 (3) 19 (4) 7 (2) 7 (4)
Sexually active
Yes 243 (52) 136 (31) <.0001 140 (47) 59 (37) .063
Missing 47 (10) 78 (18) 24 (8) 22 (14)
Educational levela <.0001 <.0001
Low 114 (24) 45 (10) 79 (27) 15 (9)
Medium 251 (54) 246 (57) 168 (57) 102 (64)
High 82 (18) 116 (27) 41 (14) 35 (22)
Missing 21 (5) 27 (6) 9 (3) 8 (5)
Currently smoking 53 (11) 35 (8) .099 43 (15) 12 (8) .029
Stage of cancer .076 .731
1 119 (25) 82 (19) 123 (41) 63 (39)
2 198 (42) 195 (45) 88 (30) 46 (29)
3 124 (27) 136 (31) 77 (26) 48 (30)
4 27 (6) 21 (5) 9 (3) 3 (2)
Type of treatment .790 .102
Surgery only 334 (71) 297 (68) 67 (23) 33 (21)
Surgery + RT 3 (1) 4 (1) 175 (59) 89 (56)
Surgery + CT 127 (27) 129 (30) 21 (7) 7 (4)
Surgery + RC + CT 4 (1) 4 (1) 34 (11) 31 (19)
Disease progression 32 (7) 30 (7) .965 26 (9) 9 (6) .230
Stoma status .986 .568
Stoma at time of surgery 20 (4) 21 (5) 97 (33) 62 (39)
Missing 126 (27) 73 (17) 62 (21) 20 (13)
Comorbidity
Cardiovascular disease 199 (43) 175 (40) .503 127 (43) 76 (48) .331
Lung disease 45 (10) 46 (11) .624 30 (10) 11 (7) .250
Diabetes mellitus 64 (14) 58 (13) .891 35 (12) 21 (13) .677
Arthrosis 90 (19) 148 (34) <.0001 57 (19) 55 (34) <.0001
Back pain 92 (20) 124 (29) .002 60 (20) 51 (32) .006
Depression 12 (3) 34 (8) <.0001 29 (6) 13 (8) .490
Abbreviations: SD = standard deviation, BMI = Body Mass Index, RT = radiotherapy, CT = chemotherapy.
a Educational level: low (no or primary school); medium (lower general secondary education or vocational training); high (pre-university
education, high vocational training, university). Note: A p-value of <.05 is considered signiﬁcant (in bold).
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symptoms (R2 = 20%; p < .0001). For women, lower
SE was associated with having cardiovascular disease
and surgery in combination with radiotherapy and che-
motherapy (R2 = 26%; p = .05).
4. Discussion
Male colon- and rectal cancer survivors were less sex-
ually active and reported worse SF compared with the
normative population. These diﬀerences were clinically
meaningful.
The ﬁndings on the prevalence of sexual dysfunction
fall within the range of previous studies.34 However, it is
not clear how to deﬁne the presence of sexual dysfunc-
tion, sexual problems and sexual disorders.35,36 In linewith the recent literature,35,37 we have excluded the score
‘a little bit’ from the deﬁnition of a sexual problem. As a
consequence, sexual dysfunction is only present when
dysfunction is severe. Moreover, it is important to know
to which extent patients are bothered by their sexual
problems (i.e. their quality of sexual life). Having a sex-
ual dysfunction may lead to a diminished quality of sex-
ual life, though this is not a necessity. In this light, the
DSM-IV formulated two separate categories to describe
sexual disorders.37 The A category focuses on deﬁning
sexual disorders per se, with the common denominator
being: ‘persistent or recurrent’, while the B category
adds a distress dimension to all dysfunctions ‘the distur-
bance causes marked distress or interpersonal diﬃ-
culty’.36,37 These deﬁnitions are a prerequisite to
distinguish a dysfunction from its emotional impact.36
Table 2
Demographic and clinical characteristics according to sexual activity and sex.
Men p-Value Women p-Value
Not sexually active
N = 311
Sexually active
N = 383
Not sexually active
N = 299
Sexually active
N = 195
Age at time of survey (mean ± SD) 72.0 ± 8.5 66.9 ± 9.4 <.0001 71.8 ± 8.8 62.8 ± 9.6 <.0001
Years since initial diagnosis (mean ± SD) 3.8 ± 2.4 3.9 ± 2.4 .480 3.9 ± 2.5 3.9 ± 2.5 .729
BMI (mean ± SD) 26.9 ± 4.0 26.8 ± 4.2 .703 27.0 ± 5.7 26.2 ± 4.7 .164
N (%) N (%) N (%) N (%)
Having a partner
Yes 239 (77) 348 (91) <.0001 148 (51) 168 (87) <.0001
Missing 6 (2) 4 (1) 11 (4) 1 (1)
Educational levela <.0001 <.0001
Low 65 (22) 38 (10) 99 (35) 26 (14)
Medium 167 (56) 223 (59) 158 (55) 142 (74)
High 69 (23) 115 (31) 28 (10) 24 (13)
Missing 10 (3) 7 (2) 14 (5) 3 (2)
Currently smoking 36 (12) 57 (15) .203 24 (8) 19 (10) .508
Rectal cancer 133 (43) 140 (37) .096 79 (26) 59 (30) .353
Stage of cancer .595 .711
1 105 (34) 112 (29) 67 (22) 47 (24)
2 113 (36) 145 (38) 127 (43) 73 (37)
3 77 (25) 107 (28) 92 (31) 67 (34)
4 16 (5) 19 (5) 13 (4) 8 (4)
Type of treatment .055 .188
Surgery only 157 (51) 195 (51) 169 (57) 91 (47)
Surgery + RT 86 (28) 77 (20) 46 (15) 34 (17)
Surgery + CT 55 (18) 88 (23) 66 (22) 55 (28)
Surgery + RC + CT 13 (4) 23 (6) 18 (6) 15 (8)
Disease progression 28 (9) 26 (7) .279 20 (7) 14 (7) .833
Stoma status .037 .997
Stoma at time of surgery 60 (25) 53 (17) 43 (17) 31 (17)
Missing 68 (22) 79 (21) 44 (15) 11 (6)
Comorbidity
Cardiovascular disease 147 (48) 158 (41) .112 142 (48) 70 (36) .011
Lung disease 37(12) 30 (8) .071 35 (12) 14 (7) .100
Diabetes mellitus 49 (16) 42 (11) .063 54 (18) 14 (7) .001
Arthrosis 69 (22) 72 (19) .270 118 (40) 57 (29) .020
Back pain 67 (22) 79 (21) .768 92 (31) 63 (32) .719
Depression 14 (5) 15 (4) .702 28 (9) 15 (8) .519
Abbreviations: SD = standard deviation, BMI = Body Mass Index, RT = radiotherapy, CT = chemotherapy.
a Educational level: low (no or primary school); medium (lower general secondary education or vocational training); high (pre-university
education, high vocational training, university). Note: A p-value of <.05 is considered signiﬁcant (in bold).
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ing sexual disorders per se). However, future research
should also include the B category in order to provide
a complete picture.
Consistent with previous studies, this study showed a
strong relationship between male SF and age,38,39 and
the presence of a stoma.7,40 Rather unexpected were
the ﬁndings that radiotherapy, chemotherapy and hav-
ing a stoma were not signiﬁcantly associated with SF.
Especially, since the role of radiotherapy is one of the
most robust ﬁndings in the literature.41 Perhaps, the
QLQ-C38 is not the most appropriate instrument to
assess this theme (see below). This study also examined
the relationship between psychological factors and SF
and SE, since it has been suggested that depression
may be a more important factor in sexual dysfunction
than clinical factors.41,42 However, only a few studies
have included this aspect.10–12 We showed that depres-sion was negatively associated with SF and SE. More-
over, fatigue was negatively associated with SF and
female SF. These ﬁndings show that the existence of sex-
ual problems in colorectal cancer patients should not
merely be attributed to treatment damage, since sexual
dysfunction is often multifactorial with biological, psy-
chological and/or social causes.
Strengths of the current study are the fact that a nor-
mative population with a similar age- and sex-distribu-
tion is included. Up to date, no large population-based
studies comparing sexual (dys)function in colorectal
cancer survivors and a normative population are avail-
able. This study contributes to the debate on whether
sexual dysfunction in a higher age is normal or patho-
logical. The current study achieved a high response rate
for both men (76%) and women (70%). Moreover, most
studies on sexual function focus on rectal cancer survi-
vors,34 since it is expected that especially they will report
Se
xu
al 
fun
cti
on
ing
Se
xu
al 
en
joy
me
nt
Er
ec
tile
 fu
nc
tio
nin
g
0
20
40
60
80
100
Colon cancer survivors
Rectal cancer survivors
Normative population
*
†
†
±
Mean
group
scores
 Sexual problems in men
Fig. 2A. Comparison of sexual problems (mean scores) in men between (i) colon cancer survivors compared with the normative population, (ii)
rectal cancer survivors compared with the normative population, and (iii) colon versus rectal cancer survivors.
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Fig. 2B. Comparison of sexual problems (mean scores) in women between (i) colon cancer survivors compared with the normative population, (ii)
rectal cancer survivors compared with the normative population, and (iii) colon versus rectal cancer survivors. *The contrast is signiﬁcant between
patients with colon cancer and the normative population. The contrast is signiﬁcant between patients with rectal cancer and the normative
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radio(chemo)therapy. This study consisted of both rec-
tal- and colon cancer survivors. We have shown that
colon cancer survivors and women also need attention
for their potential sexual problems. Finally, this study
had few missing data on sexual questions compared with
other studies.43,44 For instance, Bloemen et al.43
reported that 33% of the women did not complete the
sexuality items, while another study reported an evenhigher percentage (58%).44 In our study, less than 10%
of the men did not complete the items on sexuality, with
exception of item on SE (17% was missing). Missing
data in women ranged from 12% (dry vagina) to 17%
(sexually active).
There are also some limitations that need to be
acknowledged. First, this study is cross-sectional. As a
consequence, this design does not allow making causal
inferences or displaying short-term and long-term
Table 3
Multivariate regression analyses of sexual functioning, sexual enjoyment and male/female sexual problems in colorectal cancer survivors.
Sexual functioning
(n = 829)
Sexual enjoyment
(n = 370)
Male sexual functioning
(n = 258)
Female sexual functioning
(n = 144)
b-Value p-Value b-Value p-Value b-Value p-Value b-Value p-Value
Age at time of survey –.274 <.0001 –.175 .001 .316 <.0001 .003 .975
Men (versus women) .242 <.0001 .286 <.0001 NA NA NA NA
Years since diagnosis .038 .197 .048 .321 .047 .426 .063 .473
Having a partner .148 <.0001 NA NA NA NA NA NA
Educational level
Lowa –.110 .004 –.053 .341 –.066 .294 .046 .670
Middlea –.070 .057 –.021 .697 –.027 .653 .110 .269
BMI –.051 .087 –.020 .693 –.042 .474 –.082 .373
Smoker .037 .218 –.028 .586 .095 .118 .046 .609
Rectum (versus colon) –.133 .006 –.054 .483 .088 .322 .028 .844
Type of treatment
Surgery + RTb .042 .364 –.029 .695 .133 .129 .224 .095
Surgery + CTb .008 .792 .036 .490 –.045 .483 .163 .070
Surgery + RT + CTb –.005 .891 .053 .404 .102 .163 .084 .475
Disease progression –.027 .369 –.014 .771 .060 .300 –.060 .483
Stoma –.016 .628 –.022 .677 .232 <.0001 .146 .137
Cardiovascular disease –.006 .856 .141 .005 –.043 .472 –.090 .295
Diabetes mellitus –.046 .128 –.002 .966 .062 .282 –.089 .305
Anxiety .066 .087 .064 .316 –.118 .089 .157 .185
Depression –.132 .001 –.271 <.0001 .058 .450 –.200 .095
Fatigue –.175 <.0001 –.030 .639 .067 .362 .257 .048
Note: A p-value of <.05 is considered signiﬁcant (in bold). For the sexual functioning and enjoyment scale a positive b-value indicates better
functioning, while for the male and female sexual functioning scales a positive b-value indicates more problems.
Abbreviations: BMI = Body Mass Index, RT = radiotherapy, CT = chemotherapy, NA = not applicable.
a The middle and low educational levels were compared with a high educational level.
b These treatments were compared with surgery only.
3168 B.L. Den Oudsten et al. / European Journal of Cancer 48 (2012) 3161–3170changes in SF over time. However, knowledge about the
course of sexual (dys)function will help clinicians inform-
ing their patients in what to expect during and after treat-
ment. Second, no information was known about sexual
(dys)function before diagnosis/treatment of cancer,
which limits the determination of the eﬀect of a cancer
diagnosis and treatment on functioning or being able to
correct for baseline functioning. Prospective studies with
an assessment point prior to surgical treatment are war-
ranted. Third, even though the EORTC QLQ-CR38 is
one of the most commonly used questionnaire to assess
SF, it provides only limited information. The question
‘Did you experience diﬃculties ejaculating?’ for men
may be inadequate, since some men with colon or rectal
cancer end up with nerve damage or changes from sur-
gery, pelvic (chemo)radiotherapy or a combination so
that they essentially have ‘dry orgasms,’ with pleasurable
sensation and muscle contractions but no semen. As a
consequence, it is unknown if men had dry orgasms or
were not been able to reach orgasm. Finally, men from
the normative population did not complete the question
regarding ejaculation. Therefore, comparison with survi-
vors was not possible on male SF.
Future prospective studies should investigate sexual-
ity from a biopsychosocial model, in which the subjective
evaluation of sexual (dys)function is taken into account.
Thus, it would be interesting to assess the extent to which
patients are bothered by sexual problems, since the pres-ence of dysfunction may lead to a diminished quality of
sexual life, though this is not a necessity.34
In conclusion, this study showed that male colorectal
cancer survivors were less sexually active and reported
worse SF compared with the normative population.
These results imply that attention towards sexual
(dys)function in colorectal cancer survivors, in both
research and clinical practice is needed.
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